Evogene Ltd. · NASDAQ:EVGN
Evogene — Investor Presentation (February 2021)
38 slides from Evogene's investor presentation, February 2021

Slide 1: Investor Presentation
INVESTOR PRESENTATION Ofer Haviv, President & CEO February 2021

Slide 2: Forward Looking Statement
Forward Looking Statement This presentation contains "forward-looking statements" relating to future events, and we may from time to time make other statements, regarding our outlook or expectations for future financial or operating results and/or other matters regarding or affecting Evogene Ltd. or

Slide 3: Agenda
Agenda Introduction Fields of activity Summary Annex I - Technology Annex II - Financial Fundamentals 3

Slide 4: Our Vision: Decoding Biology
OUR VISION DECODING BIOLOGY Revolutionizing life-science product discovery & development, utilizing cutting edge computational biology technologies. 4

Slide 5: Life-science product discovery & development challenges
Life-science product discovery & development challenges High cost, long time-to-market and low probability of success Ag-chemicals Pharmaceutical Industry Industry Discovery and CDER’S* annual novel development costs drug approvals: of a new crop 2010-2019 protection product Source: Phillips McDouga

Slide 6: The opportunity
HUMAN HEALTH The opportunity Utilize comprehensive and integrated computational biology to substantially increase the probability of success, while reducing the time and cost of life-science product discovery & AGRICULTURE development. OTHER INDUSTRIES 6

Slide 7: When biology meets disruptive technologies
When biology meets disruptive technologies; introducing– platform BIOLOGY Incorporating deep scientific understandings together with big data and advanced artificial intelligence technologies (AI), seeking to BIG DATA AI successfully discover & develop novel life- science based products. Developed o

Slide 8: Tailor-made Engines for product discovery & development
Tailor-made Engines for product discovery & MICROBES development The CPB platform enhances product discovery and development through dedicated Engines for products based on SMALL MOLECULES three core components: ▪ Microbes ▪ Small molecules ▪ Genetic elements GENETIC ELEMENTS 8

Slide 9: Tailor-made Engines for product development
Tailor-made Engines for product development MICROBES Discovery Computational selection of the most promising candidates to initiate the product development process. BIOLOGY SMALL MOLECULES Development BIG DATA AI Computational driven solution addressing optimization development challenges for the se

Slide 10: GO-Genome AI genome-editing capabilities
“G O-Genome - Genome-editing capabilities AI” A first version of our artificial intelligence-driven platform was successfully designed for hundreds of unique gRNAs for 5 different genomes, applicable in pharma, agriculture and aquaculture Unique cross genomes database 10

Slide 11: Business Model: Product development through collaborations
1 Business Model Product development through collaborations Joint development with leading companies for defined products utilizing Evogene’s unique solution. Later-stage development and commercialization of the product will likely be done by the partner. Potential revenue for Evogene • Licensing an

Slide 12: Business Model: Product development through subsidiaries
2 Business Model Product development through subsidiaries Establish independent entities focusing on a defined commercial field with an exclusive license to use Evogene’s unique solutions for product development. The subsidiary may develop and commercialize products independently or through strategi

Slide 13: Agenda
Agenda Introduction Fields of activity Summary Annex I - Technology Annex II - Financial Fundamentals 13

Slide 14: Potential fields of activity
Potential fields of activity OTHER HUMAN HEALTH AGRICULTURE INDUSTRIES MICROBES SMALL MOLECULES GENETIC ELEMENTS 14

Slide 15: Current life-science based products under development
Current life-science based products under development OTHER HUMAN HEALTH AGRICULTURE INDUSTRIES Microbiome MICROBES based Ag-Biologicals Therapeutics SMALL MOLECULES Drugs based on Ag-Chemicals small molecules GENETIC ELEMENTS Ag-solutions Medical Seed Traits for castor Cannabis oil production 15

Slide 16: Development & commercialization through subsidiaries and collaborations
Development & commercialization through subsidiaries and collaborations OTHER HUMAN HEALTH AGRICULTURE INDUSTRIES MICROBES SMALL MOLECULES * GENETIC ELEMENTS Seed Traits [division] * non-exclusive license 16

Slide 17: Evogene group
Evogene group Human Other Health Agriculture Industries 90%* 100%* 98%* 72%* Internal division of Evogene 100%* Microbiome based Medical Cannabis Ag Chemicals Ag Biologicals Seed Traits Castor Oil Therapeutics Production • Immuno-oncology • Stable high yield of • Herbicides • Bio-Stimulants • Yield

Slide 18: Human Microbiome: Mission and Product Pipeline
| Human Microbiome Mission: Discovery and development of novel therapies for microbiome-related human disorders using computational biology. Product Pipeline: Expected main near-term value drivers: Immuno-oncology program: 2020 • Combination therapy for cancer with checkpoint inhibitors ✓ Extend pre

Slide 19: Human Microbiome: Example Results
| Human Microbiome Example Results: Immuno-Oncology program – BMC128 potentiate the effect of anti-PD-1 therapy (immunotherapy) in-vivo Improved antitumor activity in mice following the administration of BMC128, compared to treatment with immunotherapy alone 19

Slide 20: Medical Cannabis: Mission and Product Pipeline
| Medical Cannabis Mission: Commercialize precise & stable medical cannabis products for better therapeutic effects using computational biology. Product Pipeline: Expected main near-term value drivers: MetaYield Products: 2020 ✓ Conduct pre-clinical studies to support the • Stable enhancement of tot

Slide 21: Medical Cannabis: Example Results
| Medical Cannabis Example Results: MetaYield products under development – increased compounds per area, addressing the T20/C4 (THC16%- 24% and CBD 0%-7%) market segment, which currently consists of 70% of the Israeli medical cannabis market Medical Cannabis aiming at high THC, high yield, big inflo

Slide 22: Ag-Chemicals: Mission and Product Pipeline
| Ag-Chemicals Mission: Design of next-generation effective, sustainable and safer crop protection products by leveraging computational biology and chemistry. Product Pipeline: Expected main near-term value drivers: Herbicides: 2020 • Novel MoA (Mode-of-Action) selective/non-selective ✓ Sign collabo

Slide 23: Ag-Chemicals: Example Results
| Ag-Chemicals Example Results: Leading novel MoA herbicide candidate – displaying efficacy in eradicating multiple important weed species in field tests (weed) Field test of APH1 against a panel of grass and broadleaf weeds – untreated control vs APH1 23

Slide 24: Ag-Biologicals: Mission and Product Pipeline
| Ag-Biologicals Mission: Improve food quality, sustainability and agricultural productivity through the introduction of microbiome based ag-biological products using computational biology. Product Pipeline: Expected main near-term value drivers: Bio-stimulants (live microbials for yield improvement

Slide 25: Ag-Biologicals: Example Results
| Ag-Biologicals Example of treatment with LAV312 against Botrytis Cinerea in vines – untreated control vs treated vines Lavie Bio’s wheat field in the USA during harvest 25

Slide 26: Subsidiaries - expected main near-term value drivers
Subsidiaries - expected main near-term value drivers (as presented at the beginning of 2020) 2020 2021 2022 Initiate first GMP Extend pre-clinical Proof of concept, first in Extend pre-clinical production of drug study in Inflammatory man study, in the study in immuno- candidates in immuno- Bowel Di

Slide 27: Agenda
Agenda Introduction Fields of activity Summary Annex I - Technology Annex II - Financial Fundamentals 27

Slide 28: Summary
Summary Our mission-Improvement of life-science product Dual based business model – utilizing Evogene’s solutions for: development utilizing cutting edge computational biology 1. Product development through collaborations technologies 2. Product development through subsidiaries CPB platform - a uniq

Slide 29: Thank You
+ THANK YOU! evOgene ' be

Slide 30: Annex I: Technology
Annex I: Technology evOgene DECODING BIOLOGY -*K 30

Slide 31: The challenge in creating life-science based products
The challenge in creating life-science based products Discovery Development Product Candidate Efficacy Safety Selectivity Shelf-life Other Product Definition Selection Launch 31

Slide 32: The challenge in creating life-science based products
The challenge in creating life-science based products Common practice Discovery – selection of product candidates mainly addressing efficacy Product Candidate Efficacy Safety Selectivity Shelf-life Other Product Definition Selection Launch 32

Slide 33: The challenge in creating life-science based products
The challenge in creating life-science based products Common practice Discovery – selection of product candidates mainly addressing efficacy Development – inefficient optimization & difficulty in addressing a single challenge without impairing others Low probability of success Long time to market Hi

Slide 34: Evogene's AI-based solution: Discovery
Evogene’s AI-based solution: Discovery A multi-attribute computational selection of product candidates, addressing relevant challenges using dedicated training data sets and AI. Product Candidate Efficacy Safety Selectivity Shelf-life Other Product Definition Selection Launch 34

Slide 35: Evogene's AI-based solution: Development
Evogene’s AI-based solution: Development A multi-attribute computational analysis, addressing a specific development challenge of the selected candidate, without impairing its ability to address other product attributes. Product Candidate Efficacy Safety Selectivity Shelf-life Other Product Definiti

Slide 36: Evogene's AI engines provide tailor-made solutions
Evogene’s AI engines provide tailor-made solutions Discovery Computational prediction of candidates, to serve as the product’s core-component, addressing multiple key product attributes. Development Computational driven solution for guiding and assessing the optimization process of the selected core

Slide 37: Annex II: Financial Fundamentals
Annex II: Financial Fundamentals 37

Slide 38: Key Financials: Balance Sheet
Key Financials: Thousands of US $ 30.09.2020 31.12.2019 Balance Sheet Current Assets 45,392 49,027 Long-Term Assets 20,593 22,337 Total Assets 65,985 71,364 Current Liabilities 4,639 5,746 Key Points: • Consolidated cash position: ~$43.5 million as of Long-Term Liabilities 5,276 5,401 30.09.2020. •
Source: Internet Archive copy of evogene.com
More decks from Evogene Ltd.
Investor Presentation (August 2026)32 slides · Aug 27, 2026
Q2 2026 Earnings Presentation18 slides · Aug 18, 2026
Investor Presentation (June 2026)32 slides · Jun 16, 2026
Q1 2026 Earnings Presentation27 slides · May 20, 2026
Investor Presentation (April 2026)27 slides · Apr 28, 2026
Investor Presentation (March 2026)26 slides · Mar 12, 2026